PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'VIB Center for Inflammation Research, Ghent, Belgium and Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.\', \'University Hospital Ghent, Ghent, Belgium.\', \'VIB-UGent Center for Inflammation Research, Ghent, Belgium.\', \'UCB Biopharma SRL, Braine-l\'Alleud, Belgium.\', \'UCB Pharma, Slough, UK.\', \'Ghent University, Ghent, Belgium.\', \'VIB Center for Inflammation Research, Ghent, Belgium and Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. bart.lambrecht@ugent.be.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04884-0
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 33213529
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all